Dataset from A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Two-Part Crossover Study in Healthy Subjects to Compare the Bioavailability of Dexlansoprazole From Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda GmbH Plant Oranienburg Relative to Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda Pharmaceutical Company Limited Osaka Plant
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00007407
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30
milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant
Oranienburg, Germany (TOB) relative to that of dexlansoprazole from a 30 mg or 60 mg capsule
manufactured at Takeda Pharmaceutical Company Ltd. (Osaka, Japan) (TPC).
创建时间：
2025-10-01
